This year the mid year meeting of the International Society of Pharmacoepidemiology and pharmacovigilance (ISPE) will be held April 6-9 in Rome. The meeting will focus on biologicals and biosimilars. During the meeting different perspectives on the use of biologicals from regulatory agencies, industry and scientific society will be discussed and RWE on biologicals and biosimilars will be highlighted.
The topic of this years mid year meeting, biologicals and biosimilars, fully aligns with PHARMO’s ambitions of the last couple of years to become a key player in the field of biologicals and biosimilars. These types of drugs are captured in our pharmacy databases, which include detailed information on type of product, brand, date, strength, dosage regimen, quantity, route of administration and prescriber specialty. In addition, we develop disease cohorts, focusing on indications that are treated with biologicals such as inflammatory bowel disease (IBD). This cohort contains over 9,000 patients with either Crohn’s disease (CD) or ulcerative colitis (UC). Of these patients data is available on patient and disease characteristics, treatment and outcomes, such as healthcare resource utilisation. Of the 9,000 patients included in the IBD cohort, 18% of the patients with CD and 5% of the patients with UC were treated with biologicals. The majority of these patients were treated with adalimumab.
In addition to the scientific content, the mid year meeting will be a great opportunity to catch up with our clients and collaborators. We hope to see you there!
For more information on the ISPE mid year meeting or to register, please visit the website.
If you would like to schedule a meeting with the PHARMO team during the mid year meeting, please contact us beforehand on email@example.com